

Kristina M. Brooks,¹ Jennifer J. Kiser,¹ Yasha Rani,² Gaerolwe R. Masheto,³ Faezeh Patel,⁴ Iris Mustich,⁵ Barbara Heckman,⁶ Mark Lojaco,⁶ Dwight E. Yin,⁷ Sai Majji,⁸ Hardik Chandasana,⁹ Helena Rabie,¹⁰ Patricia Flynn,¹¹ on behalf of the IMPAACT 2019 Team

¹Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA ²Frontier Science & Technology Research Foundation (FSTRF), Brookline, MA, USA ³Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, USA ⁴WRHI Shandukani Research Centre, Johannesburg, South Africa ⁵FHI 360, Durham, NC, USA ⁶Frontier Science & Technology Research Foundation (FSTRF), Inc., Amherst, NY, USA ⁷National Institute of Allergy and Infectious Diseases, Rockville, MD, USA ⁸National Institute of Child Health and Human Development, Bethesda, MD, USA ⁹GlaxoSmithKline, Collegeville, PA, USA ¹⁰University of Stellenbosch, Stellenbosch, South Africa, USA ¹¹St. Jude Children's Research Hospital, Memphis, TN, USA

BACKGROUND

- There is limited availability of pediatric-friendly fixed dose combination (FDC) antiretroviral formulations.
- Abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) is only available as an immediate-release FDC tablet for use in adults and children ≥40 kg.¹
- IMPAACT 2019 is examining the pharmacokinetics (PK), safety, and tolerability of ABC/DTG/3TC in immediate- and dispersible-release FDC form.
- Doses of individual components align with WHO weight band dosing.
- We previously confirmed dosing for the immediate-release, adult strength FDC tablet in children weighing ≥25 to <40 kg, and the novel dispersible-release FDC tablets in children weighing 14 to <25 kg.^{2,3}
- Here, we report PK and week 4 safety results in children weighing 6 to <14 kg.

OBJECTIVES

- To determine steady-state area under the concentration time curve over 24 hours (AUC_{0-24h}), maximum concentration (C_{max}), and concentration at 24 hours post-dose (C_{24h}) of ABC, DTG, and 3TC.
- To confirm dosing of ABC/DTG/3TC dispersible- and immediate-release tablets that achieve protocol-defined PK targets for ABC, DTG, and 3TC.

METHODS

- Phase I/II, multi-site, open-label, non-comparative dose confirmation study (NCT03760458)
- Study sites in Botswana, South Africa, Thailand and the United States
- Plasma ABC, DTG, and 3TC concentrations quantified using liquid chromatography mass spectrometry (LC/MS) methods
- PK parameters calculated using noncompartmental methods (Phoenix WinNonlin®, Certara, Inc.)

FIGURE 1. IMPAACT 2019 Weight Bands

WB1 (6 to <10 kg)	ABC 180mg/DTG 15mg/3TC 90mg • 3 DT dispersed in 15 mL water
WB2 (10 to <14 kg)	ABC 240mg/DTG 20mg/3TC 120mg • 4 DT dispersed in 20 mL water
WB3 (14 to <20 kg)	ABC 300mg/DTG 25mg/3TC 150mg • 5 DT dispersed in 20 mL water
WB4 (20 to <25 kg)	ABC 360mg/DTG 30mg/3TC 180mg • 6 DT dispersed in 20 mL water
WB5 (≥25 kg)	ABC 600mg/DTG 50mg/3TC 300mg • 1 IR tablet swallowed whole

DT: dispersible-release tablet; IR: immediate-release; WB: weight band.


Key Eligibility Criteria:

- Age <12 years
- Weight 6 to <40 kg
- Confirmed HIV infection
- Treatment-naïve or
- Treatment-experienced with HIV VL <200 copies/mL on a stable non-NNRTI-containing ARV regimen for ≥6 months

Dosing of dispersible release ABC/DTG/3TC FDC tablets was confirmed in alignment with WHO weight band recommendations in children 6 to <14 kg

METHODS

FIGURE 2. Dose Confirmation Approach



RESULTS


- 16 participants were enrolled for dose confirmation, of which two (1 in WB1 and 1 in WB2) withdrew prior to the intensive PK assessments due to palatability issues. Resulting data reflect those who underwent intensive PKs.

TABLE 2. Participant Demographics & DOT Methods

Characteristic	WB1 (N=7)	WB2 (N=7)
Sex at birth, n(%)		
Female	5 (71%)	4 (57%)
Male	2 (29%)	3 (43%)
Age (year), median (range) ^a	1.6 (1.1-2.0)	3.6 (2.1-4.0)
Weight (kg), median (range) ^a	9.5 (8.3-9.8)	13.1 (11.2-14.2)
Treatment-Experienced, n(%)	5 (71%)	7 (100%)
DOT method, n(%) ^b		
In-person	84 (100%)	42 (44%)
Real-time video	--	54 (56%)
Recorded timestamped video	--	--

^a On day of intensive PK ^b n(%) reflective of total number of dosing events

FIGURE 3. PK Results by Weight Band with Comparison to PK Targets and Historical Data



Key: dashed lines (---) indicate individual DTG target (minimum). Gray shading (■) indicates weight band target ranges. Dotted lines (···) indicate GM measures in adults with HIV receiving DTG 50 mg, ABC 600 mg, or 3TC 300 mg once-daily. Black diamond (◆) indicates predicted GM measures in children with HIV receiving same weight band doses of each component (compiled from FDA Clinical Pharmacology Reviews). Data presented from all five weight bands for side-by-side comparison of dose confirmation results.^{2,3} Two participants in WB1 (0.47 and 0.45 ug/mL) and one participant in WB2 (0.35 ug/mL) did not meet the individual DTG C_{24h} targets but met the individual AUC_{0-24h} targets. All C_{24h} were above the EC₉₀ of 0.3 ug/mL for DTG and no individual dose adjustments were made.

TABLE 1. Individual & Weight Band Targets

Drug	PK Parameter	Individual Target	Weight Band Target ^a
DTG	AUC _{0-24h} (µg·h/mL)	25.0 ^b -134	35.1 ^c -134 ^d
	C _{24h} (µg/mL)	≥0.5 ^b	0.67 ^e -2.97 ^f
ABC	AUC _{0-24h} (µg·h/mL)	--	6.3-50.4 ^g
	3TC AUC _{0-24h} (µg·h/mL)	--	6.3-26.5 ^g

^aGeometric mean for the weight band must fall within these targets ^bEstimated DTG AUC_{0-24h} and C_{24h} values to produce EC₉₀ ^cLower 90% CI bound for once-daily DTG exposures in adults ^dUpper 90% CI bound for twice-daily DTG exposures in adults ^eTargets based on 60% of once-daily DTG exposures in adults ^fTargets based on 140% of twice-daily DTG exposures in adults ^gMinimum lower and maximum upper 90% CI bounds for predicted once-daily ABC and 3TC exposures in children based on population PK modeling of ARROW, PENTA13, PENTA15, and other single-dose PK studies in children

PK and safety criteria had to be met for dose confirmation within each WB

RESULTS (CONTINUED)

- No grade 3 or higher AEs related to study drug
- No children discontinued study drug due to AEs
- No AEs required intervention

TABLE 4. Summary of AEs through Study Week 4

WB	Grade	Event	Time on Study Drug	Relationship	Time to Resolution
1	3	Fever (due to tonsillitis)	2+ weeks	Not related	Same day
	2	eGFR decrease ^a	4 weeks	Related to DTG	Ongoing
	1	SCr increase ^a	4 weeks	Related to DTG	Ongoing
1	1	ALT increase	4 weeks	Related to DTG, ABC, and 3TC	~4 weeks

Key: ALT = alanine transaminase; eGFR = estimated glomerular filtration rate; SCr = serum creatinine. ^aIn same participant; severity grading based on change from baseline; absolute values were within normal limits.

CONCLUSIONS

- PK targets were met for dispersible release ABC/DTG/3TC in children 6 to <14 kg.
- This formulation was well tolerated, and results provide reassurance for dosing of this FDC formulation.
- Longer-term safety, tolerability, and efficacy data through 48 weeks in all weight bands are forthcoming.
- Findings expected to support global efforts to expand the availability of pediatric-friendly DTG-containing FDCs in alignment with WHO weight band dosing.

ACKNOWLEDGEMENTS

The study team would like to sincerely thank the **study participants and caregivers**.

We would also like to thank Viiv/GlaxoSmithKline and the following study sites: Lurie Children's Hospital of Chicago (4001) (E. Chadwick, MD; Karen C. Sheriff, APN; M. A. Sanders, MPH); University of Colorado Denver NICHD CRS (5052) (L.L. Abougi, MD, MSc; J. Dunn, MS, FNP; C. Glenny, BSN, MA, RN; S. Curran-Hays, MS); Rush University Cook County Hospital Chicago NICHD CRS (5083) (M. Aziz, MD; M. McNichols, MSN, RN, CCRP; I. Ortiz-Estes, MSN, C-PNP); David Geffen School of Medicine at UCLA NICHD CRS (5112) (M.F. Carter, BS; E.C. Lang, CCRP; H. Mansky, PharmD; I. dos Santos); Siriraj Hospital, Mahidol University NICHD CRS (5115) (K. Chokephaibulkit, MD; N. Vanparapar, MD, MSc; N. Kongstan, BN, MSc; W. Lermankul, BPharm, PhD); Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Rai, Thailand (5116) (P. Ounchanum, MD; P. Sukrakanchana, BSN; N. Krapunongsakul, BSN); St. Jude Children's Research Hospital CRS (6501) (N. Patel, MD; A. English, RN; H. Allen, NP; C. London, NP); Wits RHI Shanukani Research Center CRS (8051) (F. Patel, MBChB; M. Dhar, MBBS; R. Komane, BNS; S. Phathokuhle, B Cur); Soweto IMPAACT CRS (8052) (V. Khemese, RN; N. Hilda Ndiweni, B.Cur.; T. Madonsela, B.Cur.; N. Ramsagar, BSc Hons); FAM_CRU CRS, Tygerburg Hospital (8950) (E Dobbels, FC PAED; P Zuidewind, MBChB; W Orange, Enrolled nursing certificate); Gaborone CRS (12701) & Molepolole CRS (12702), Botswana Harvard AIDS Institute Partnership (M. Budu, MD; M.S. Raesi, BScN; B. Seme, RN; M. Ramogodiri, RN), Umlazi CRS, Prince Mshiyeni Memorial Hospital (30300) (K. Naidoo, MBChB, PhD; M. Naidoo, MbChB; V. Govender, Honors Medical Biochemistry; R. Gazu, National Diploma Nursing and Midwifery), CMU HIV Treatment CRS, Chiang Mai University (31784) (L. Aurpibul, MD, MPH; C. Khamrong, MSc; R. Thammalangka, RN; J. Chanthong, BSc, RN). The University of Colorado is a Certara Center of Excellence school. The Center of Excellence program supports leading institutions with Certara's state of the art model-informed drug development software.

REFERENCES

- Triumeq® [Package Insert]. Research Triangle Park, NC; Viiv/GlaxoSmithKline; 2021.
- Brooks KM, Kiser JJ, Samson P, et al. Reviews in Antiviral Therapy & Infectious Diseases 2021;5:3. (3) Brooks KM, Kiser JJ, Samson P, et al. International AIDS Society (IAS) 2021 Conference; 18-21 Jul 2021; Virtual.